Senior Director, Clinical Development

·         Primary point of contact for clinical development activities with willingness to work strategically and hands on at the program and clinical trial levels.

·         Accountable for the oversight, monitoring and surveillance of overall risk, safety, benefit/efficacy to patients as well as compliant trial execution and optimal integrity of data.

·         Responsible for establishing relationships and communication with KOLs, investigators and relevant site medical (or other supportive roles) personnel.

·         Lead the clinical development strategy and innovative approaches for the overall clinical pathway for the asset.

·         Key clinical development contributor to publication strategy and planning, authoring of publications, posters, etc., and present or support presentations, posters, etc., in conferences and meetings.

·         Play a key role in regulatory and health authority interactions.

·         Lead clinical development contributor to regulatory activities, submissions, and clinical sections of regulatory/health authority pre-meeting packages and initial applications, routine annual reports, ad hoc safety reports (SUSARs), interim and final CSRs, etc.

·         Author asset and clinical trial level plans, charters, documents.

·         Determine optimal clinical trial design options that are innovative, patient centric, cost efficient, and enable meeting business goals.

·         Responsible for review, analysis and interpretation of all clinical trial data including assessment of protocol deviations.

·         Lead asset level clinical sub-teams and play key leadership role on program team for clinical development.

·         Lead asset level and trial level medical forums as needed (safety review committee, ad board, KOL meetings, medical review/discussions of patient cases, cohort review meetings, etc.).

·         Attend and present as needed at core team meetings, investigator meetings, site visits, etc.

·         Liaise with cross functional partners, vendors, and CROs to ensure the progression of clinical studies within the expected time frame.

·         Provide clinical evaluation and interpretation of pre-clinical results.

·         Remain current on the development of orexin agonists and the relevant therapeutic areas through review of the scientific literature, interactions with KOLs and other external experts and attendance at relevant scientific meetings, to provide input and guidance for the strategic direction of Centessa clinical stage programs.